Chief Financial Officer
Christine Siu is the chief financial officer of Eidos Therapeutics. Previously, she was the first employee at Global Blood Therapeutics, where she incubated the company with Third Rock Ventures and grew the company from drug discovery to IND-enabling studies for the lead drug to treat sickle cell disease. Before joining Global Blood Therapeutics, Christine was a venture principal at Third Rock Ventures, focused on company formation and investment due diligence. Prior to Third Rock, Christine was an investor at Thomas, McNerney & Partners and Warburg Pincus, where she invested over $400M in early stage, growth equity, public investments, and leveraged buyouts in the life sciences and health care sectors.
Christine is also the chief business officer of The Bluefield Project to Cure Frontotemporal Dementia, a medical philanthropy dedicated to curing a genetic form of early-onset dementia. She holds a MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from The University of Michigan.